Targovax ASA (GB:0RIS) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Targovax ASA, through its subsidiary Circio Holding, is collaborating with Certest Biotec to develop and test innovative circVec DNA-LNP formulations aimed at treating genetic diseases. The collaboration leverages Certest’s proprietary lipid nanoparticle technology for targeted delivery to specific tissues like the lung, liver, and spleen. Successful in vitro results have paved the way for in vivo testing, which could lead to the advancement of new therapeutic candidates.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
